format
small
interf
rna
sirna
occur
two
step
involv
bind
rna
nucleas
larg
doublestrand
rna
dsrna
cleavag
fragment
call
sirna
second
step
sirna
join
multinucleas
complex
degrad
homolog
singlestrand
mrna
deliveri
sirna
involv
viraland
nonviralmedi
deliveri
system
approach
chemic
modif
also
develop
variou
therapeut
applic
disord
like
cardiovascular
diseas
central
nervou
system
cn
disord
cancer
human
immunodefici
viru
hiv
hepat
disord
etc
present
review
give
overview
applic
sirna
potenti
treat
mani
hitherto
untreat
diseas
br
goyal
et
al
rna
interfer
also
call
rnamedi
interfer
rnai
mechan
rnaguid
regul
gene
express
doublestrand
ribonucl
acid
dsrna
inhibit
express
gene
complementari
nucleotid
sequenc
function
mediat
rnai
small
interf
rna
sirna
dsrna
shown
potent
sequencespecif
inhibitor
gene
function
nematod
caenorhabd
elegan
rnai
describ
sever
eukaryot
unicellular
organ
like
trypanosoma
brucei
also
multicellular
organ
like
c
elegan
drosophila
planaria
hydra
plant
zebrafish
mice
human
sever
observ
suggest
rnai
involv
activ
process
exampl
sirna
deliv
microinject
intestin
exert
interfer
effect
tissu
inject
anim
progeni
suggest
presenc
activ
transport
perhap
amplifi
interf
agent
technolog
extrem
use
tool
identifi
gene
function
evalu
potenti
therapeut
target
increas
number
biotechnolog
pharmaceut
compani
attempt
develop
rnaibas
drug
prevent
treatment
human
diseas
cardiovascular
diseas
neurolog
diseas
viral
infect
cancer
etc
current
mani
diseas
like
heart
failur
cancer
surgeri
remain
option
drug
treat
diseas
avail
although
sirnabas
therapi
still
infanc
hold
tremend
promis
use
routin
clinic
practic
adjunct
exist
procedur
help
overcom
limit
associ
current
therapeut
regimen
present
review
discuss
basic
sirna
therapeut
applic
technolog
variou
disord
cardiovascular
diseas
neurolog
disord
infecti
diseas
cancer
human
immunodefici
viru
hiv
hepat
disord
other
rnai
work
two
step
first
step
refer
rnaiiniti
step
involv
bind
rna
nucleas
larg
dsrna
cleavag
discret
rna
fragment
call
sirna
keyword
cancer
cardiovascular
diseas
cn
disord
deliveri
sirna
second
step
sirna
also
call
guid
rna
join
multinucleas
complex
rnainduc
silenc
complex
degrad
homolog
singlestrand
mrna
step
process
dsrna
sirna
first
dsrna
cleav
fragment
dicer
dicer
homologu
process
start
end
bluntend
dsrna
dsrna
short
overhang
proce
nucleotid
step
result
fragment
sirna
bound
rnaispecif
enzym
possibl
still
includ
dicer
could
incorpor
distinct
nucleas
complex
rnainduc
silenc
complex
complex
compris
sirna
rnaispecif
enzym
includ
dicer
nucleas
target
mrna
process
degrad
complex
sirna
pair
target
mrna
cleav
mrna
center
region
recogn
sirna
wherebi
mrna
cleavag
boundari
determin
sequenc
dsrna
figur
either
ribonucleas
cleav
dsrna
anoth
ribonucleas
recruit
cleav
target
rna
ribonucleas
temporarili
displac
passiv
sirna
strand
use
target
recognit
dsrnaprocess
protein
subset
remain
associ
sirna
duplex
process
reaction
orient
sirna
duplex
rel
protein
determin
two
complementari
strand
function
guid
target
rna
degrad
chemic
synthes
sirna
duplex
guid
cleavag
sens
well
antisens
target
rna
abl
associ
protein
compon
either
possibl
orient
antisens
strand
could
instanc
interact
directli
target
rna
wherea
sens
strand
could
indirectli
particip
rnai
eg
protect
antisens
strand
ribonucleas
step
amplif
sirna
one
mani
intrigu
featur
rna
interfer
appar
catalyt
natur
phenomenon
molecul
dsrna
suffici
degrad
continu
transcrib
target
mrna
long
period
time
although
convers
long
dsrna
mani
small
sirna
result
degre
amplif
suffici
bring
continu
mrna
degrad
recent
studi
provid
convinc
biochem
genet
evid
rnadepend
rna
polymeras
rdrp
first
identifi
plant
inde
play
critic
role
amplifi
rnai
effect
insect
rdrp
encod
gene
c
elegan
gene
neurospora
might
amplifi
dsrna
signal
produc
longlast
posttranscript
gene
silenc
absenc
dsrna
initi
effect
therebi
rdrp
might
convert
aberr
singlestrand
rna
popul
dsrna
repeatedli
copi
dsrna
produc
popul
singlestrand
rna
could
interact
target
rna
copi
copi
trigger
thu
gener
selfrepl
trigger
popul
absenc
identifi
rdrp
homologu
drosophila
mammal
suggest
either
rna
copi
enzym
use
primari
sirna
may
suffici
produc
detect
interfer
respons
regardless
whether
dsrna
signal
amplifi
natur
rdrp
activ
shown
rnai
work
better
dsrna
use
initi
process
deliveri
sirna
pose
major
challeng
far
therapeut
use
concern
howev
variou
approach
consid
tabl
chemic
modif
viral
nucleic
acid
deliveri
nonvir
nucleic
acid
deliveri
small
interf
rna
sensit
nucleas
poor
tissu
distribut
poor
membran
permeabl
henc
chemic
modif
would
help
proper
deliveri
sirna
follow
method
follow
chemic
modif
resist
sirna
nucleas
increas
chemic
modifi
nucleobas
sugar
phosphat
ester
backbon
sirna
furthermor
boranophosph
phosphorothio
lock
nucleotid
chemic
modifi
form
decreas
sensit
sirna
nucleas
modifi
sirna
membraneperm
peptid
penetratin
transportin
coupl
sirna
approach
chemic
modifi
system
result
increas
intracellular
uptak
sirna
anoth
approach
sirna
partial
phosphorothio
backbon
modif
sugar
variat
sens
antisens
strand
promot
nucleas
resist
cholesterol
conjug
sens
strand
use
pyrrolidin
linker
chang
tissu
distribut
increas
specif
secondgener
sirna
known
stealth
rnai
develop
chemic
modif
design
increas
specif
rnai
effect
allow
antisens
strand
effici
enter
rnai
pathway
elimin
induct
interferonrel
pathway
virus
bind
cell
deliv
nucleic
acid
payload
intracellularli
profici
along
nuclear
local
usual
virusmedi
deliveri
method
base
deliveri
gene
encod
short
hairpin
rna
shrna
howev
approach
use
virus
deliv
chemic
synthes
sirna
vivo
deliveri
chemic
synthes
sirna
small
interf
rna
encapsul
reconstitut
viral
envelop
deriv
influenza
viru
reconstitut
membran
vesicl
contain
influenza
viru
spike
protein
hemagglutinin
respons
bind
fusion
cellular
membran
addit
ad
cation
lipid
sirnaload
vesicl
taken
receptormedi
endocytosi
abl
escap
endosom
degrad
fusion
endosom
membran
function
sirna
deliveri
demonstr
vitro
vivo
uptak
macrophag
periton
caviti
demonstr
intraperiton
inject
similar
approach
describ
sirna
deliveri
simian
viru
particl
vitro
lymphoblastoid
cell
difficulti
repeat
administr
limit
control
transduc
cell
type
major
drawback
system
deliveri
dnaencod
sirnashrna
number
studi
investig
use
dna
encod
shrna
deliv
virus
gene
silenc
vivo
almost
complet
inhibit
viral
survivin
protein
inhibit
cancer
cell
apoptosi
mice
bear
subcutan
glioma
tumor
treat
intratumor
inject
viral
particl
three
consecut
day
everi
day
ultim
lead
fourfold
smaller
tumor
day
start
treatment
compar
empti
adenovir
vector
adenovir
vector
express
irrelev
sirna
intracrani
deliveri
lentivirusproduc
shrna
inhibit
report
gene
express
cortic
neuron
intraperiton
deliveri
lentivirusproduc
shrna
inhibit
viral
cyclin
prevent
primari
effus
lymphoma
mice
intramuscular
intraspin
deliveri
lentivirusproduc
shrna
inhibit
mutant
amyotroph
later
sclerosi
ex
vivo
deliveri
lentivirusproduc
shrna
inhibit
ccchemokin
receptor
hematopoiet
cell
mice
approach
deliv
dnaencod
sishrna
gene
silenc
taken
togeth
viral
dnabas
shsirna
deliveri
process
effici
bind
target
cell
surfac
subsequ
transduct
carrier
stabil
protect
nucleas
appear
satisfactori
howev
virus
usual
lack
select
target
cell
type
improv
specif
natur
tropism
virus
certain
cell
type
may
use
redirect
natur
prefer
cell
type
virus
toward
therapeut
interest
receptor
surfac
target
cell
one
newer
approach
studi
day
exampl
includ
retarget
murin
coronaviru
toward
human
epiderm
growth
factor
receptor
direct
adenoviru
via
fibroblast
growth
factor
ligand
toward
associ
receptor
deliveri
glioma
adenovir
deliveri
angiogen
endothelium
via
rgdpeptid
arginineglycineaspart
sequenc
peptid
bind
alpha
cintegrin
howev
approach
tri
yet
combin
rnaimedi
gene
silenc
vivo
effici
transduct
cell
main
strength
viral
deliveri
approach
howev
major
drawback
control
transduc
cell
type
especi
system
administr
inflammatori
reaction
immunogen
oncogen
transform
nonvir
nucleic
acid
deliveri
nonvir
vector
possess
sever
advantag
viral
vector
lack
immunogen
low
frequenc
integr
eas
largescal
product
major
advantag
synthet
vector
system
addit
accommod
wide
varieti
nucleic
acid
size
allow
easi
modif
howev
effici
transfect
becom
problem
overcom
mani
function
group
need
incorpor
cation
function
group
usual
requir
bind
condens
nucleic
acid
therebi
protect
nucleas
increas
appar
molecular
weight
renal
clearanc
cutoff
addit
cation
compound
use
endosom
escap
enhanc
result
posit
charg
complex
tend
form
aggreg
bind
blood
stream
neg
charg
biomolecul
result
clearanc
usual
rapid
moreov
cation
complex
possess
propens
interact
virtual
cell
type
encount
creat
need
insul
interact
surfac
particl
promot
specif
purpos
shield
group
ad
enhanc
colloid
stabil
reduc
surfac
charg
therebi
avoid
nonspecif
cell
uptak
restor
cell
interact
targetspecif
manner
target
ligand
coupl
induc
sitespecif
bind
uptak
case
deliveri
dna
encod
shrna
nonvir
deliveri
system
nuclear
transloc
dna
often
inadequ
cytoplasm
site
activ
chemic
synthes
sirna
provid
import
advantag
deliveri
system
base
rna
system
consist
complet
rna
base
packag
rna
dnapackag
motor
bacteriophag
spontan
form
dimer
via
interlock
rightand
lefthand
loop
attach
sirna
one
loop
rna
aptam
cancer
celltarget
system
creat
could
silenc
survivin
gene
express
vitro
altern
system
could
also
target
folat
unshield
untarget
complex
sirna
cation
polym
lipid
provid
local
system
transfect
suffici
number
target
cell
therapeut
effect
tumor
necrosi
factor
tnf
alpha
intraperiton
macrophag
intraperiton
administr
delta
opioid
receptor
spinal
cord
dorsal
root
ganglia
intrathec
administr
pololik
bladder
cancer
intraves
administr
prostat
cancer
cell
intraven
administr
exampl
employ
cation
lipid
complex
sirna
major
drawback
approach
nonspecif
effect
induc
cation
lipid
particular
combin
dsrna
may
sever
hamper
therapeut
applic
varieti
cation
compound
also
investig
sirnadeliveri
purpos
linear
lowmolecularweight
form
cation
polym
poli
ethylen
imin
use
treatment
subcutan
implant
ovarian
carcinoma
mice
intraperiton
administr
complex
sirna
primarili
recov
muscl
liver
kidney
tumor
silenc
polyplex
inhibit
ovarian
carcinoma
growth
vivo
highli
purifi
typei
collagen
calf
dermi
digest
pepsin
name
atelocollagen
shown
suitabl
vehicl
local
deliveri
sirna
intraven
administr
atelocollagensirna
local
site
tumor
mestastas
inhibit
metastasi
outgrowth
specif
tumor
level
increas
sixfold
compar
level
nake
sirna
administr
deliveri
level
sirna
silenc
enhanc
zest
gene
overexpress
hormonerefractori
metastat
prostat
cancer
phosphatidylinositol
regul
cell
surviv
prolifer
migrat
result
strong
inhibit
growth
bone
metastas
prostat
cancer
cell
importantli
sirnaatelocollagen
complex
fail
induc
nonspecif
proinflammatori
respons
like
secret
interferon
ifn
interleukin
il
target
cation
deliveri
system
target
amino
acidbas
system
base
cation
peptid
protamin
system
protamin
block
cterminu
heavychain
fab
fragment
envelop
antibodi
coupl
form
protein
construct
known
system
highli
effici
bind
transfect
cell
express
hivenvelop
protein
although
unclear
hivenvelop
protein
would
intern
importantli
express
interferonb
synthetas
indic
nonspecif
effect
increas
upon
sirna
transfect
hivenvelopeexpress
melanoma
cell
addit
cell
form
subcutan
tumor
vivo
cell
took
fluoresc
sirna
deliv
intraven
administr
nake
sirna
taken
deliv
cell
envelop
proteinneg
deliveri
combin
sirna
cmyc
bind
protein
homologu
vascular
endotheli
growth
factor
vegf
strongli
inhibit
tumor
growth
vivo
deliv
use
system
combin
sirna
attack
tumor
multipl
front
import
advantag
sirna
technolog
allow
simultan
interfer
number
differ
pathway
deliveri
problem
individu
drug
molecul
sirna
remain
versatil
target
system
demonstr
exchang
hivenvelop
antibodi
antibodi
thu
chang
specif
system
breast
carcinoma
cell
transferrin
receptor
singlechain
fv
region
antibodi
fragment
coupl
surfac
cation
dotap
dope
complex
contain
sirna
studi
evalu
target
potenti
system
differ
murin
tumor
model
ie
orthotop
implant
pancreat
carcinoma
produc
spontan
metastas
orthotop
implant
prostat
carcinoma
intraven
administ
breast
carcinoma
cell
give
rise
metastas
lung
model
specif
accumul
fluoresc
label
sirna
complex
target
cation
lipid
particl
site
malign
could
demonstr
compar
surround
normal
tissu
liver
shield
cation
surfac
may
enhanc
target
cell
specif
reduc
nontarget
tissu
uptak
may
addit
increas
colloid
stabil
sirna
complex
studi
cation
polym
poli
ethylen
imin
coupl
poli
ethylen
glycol
peg
act
shield
polym
distal
end
peg
chain
cyclic
rgd
peptid
coupl
highaffin
ligand
alpha
cintegrin
overexpress
angiogen
endotheli
surfac
observ
inject
nake
sirna
produc
appreci
tumor
level
rather
rapid
clearanc
urin
vivo
tissu
distribut
studi
involv
administr
fluoresc
label
sirna
subcutan
neuroblastomabear
mice
poli
ethylen
imin
pei
sirna
complex
also
lack
product
high
fluoresc
tumor
increas
liver
lung
level
pegshield
target
nanoparticl
use
higher
level
specif
tumor
lower
level
fluoresc
lung
liver
observ
anoth
studi
sirna
murin
vegf
use
deliveri
host
tumor
endothelium
requir
inhibit
tumor
prolifer
efficaci
studi
sirna
complex
rgdpegpei
nanoparticl
result
strong
inhibit
subcutan
neuroblastoma
growth
rate
sequencespecif
experi
suggest
target
shield
nanoparticl
inde
deliv
sirna
angiogen
endotheli
cell
line
find
reduc
tumor
growth
rate
parallel
reduct
blood
vessel
peripheri
tumor
chang
vascular
morpholog
remain
vessel
support
antiangiogen
mechan
action
result
support
studi
model
patholog
angiogenesi
eye
demonstr
vasculaturespecif
deliveri
inhibit
angiogenesi
lead
therapeut
effect
target
cation
system
import
advantag
possess
recognit
signal
specif
interact
target
cell
type
spite
develop
sirna
span
year
wide
potenti
applic
cardiovascular
diseas
cvd
central
nervou
system
cn
diseas
cancer
etc
applic
target
sirna
depict
figur
variou
cvd
like
hypertens
hyperlipidemia
cardiac
hypertrophi
treat
use
sirna
modif
specif
target
gene
discuss
length
follow
hypertens
increas
risk
sudden
cardiac
death
mainli
causal
associ
left
ventricular
hypertrophi
hypertens
one
import
risk
factor
stroke
congest
heart
failur
myocardi
infarct
peripher
vascular
diseas
reninangiotensin
system
play
import
role
develop
progress
devast
disord
patient
hypertens
angiotensin
ii
physiolog
activ
major
substanc
reninangiotensin
system
act
vasopressor
induc
vasoconstrict
elicit
water
sodium
absorpt
proxim
renal
tubul
stimul
secret
aldosteron
bind
two
distinct
receptor
subtyp
name
type
type
primari
subtyp
account
angiotensin
ii
action
mice
vazquez
et
al
select
r
target
gene
design
correspond
dsrna
transfect
chines
hamster
ovari
cell
cho
express
rat
r
found
decreas
level
r
mrna
furthermor
dosedepend
decreas
specif
bind
angiotensin
ii
rexpress
cho
cell
determin
whether
decreas
rspecif
bind
associ
reduct
function
r
examin
effect
dsrna
transfect
angiotensin
iistimul
calcium
uptak
dsrna
transfect
cell
angiotensin
iiinduc
increas
calcium
uptak
complet
abolish
found
knock
express
heat
shock
rnai
technolog
exacerb
angiotensin
iiinduc
inflammatori
injuri
caus
significantli
higher
activ
nuclear
factor
kappa
b
nfjb
vascular
smooth
muscl
cell
vsmc
anoth
research
mechan
hypertens
reveal
rhoarho
kinas
pathway
signific
pathway
behind
pathogenesi
abnorm
contract
vsmc
cardiovascular
diseas
knockdown
rhoa
rnai
decreas
level
rhoa
mrna
contractil
cultur
vsmc
indic
express
level
rhoa
play
critic
role
regul
contractil
dedifferenti
vsmc
rhoa
could
new
therapi
target
hypertens
thu
find
suggest
rnai
might
potenti
altern
drug
therapi
hypertens
atherosclerosi
chronic
inflammatori
diseas
arteri
intima
result
concert
action
multipl
factor
mani
studi
shown
macrophag
cell
play
critic
role
multipl
aspect
pathogenesi
diseas
adiponectin
found
enhanc
akt
phosphoryl
pretreat
akt
sirna
transfect
block
inhibitori
effect
adiponectin
tnfainduc
synthesi
porcin
coronari
arteri
smc
suggest
akt
activ
might
inhibit
synthesi
proinflammatori
chemokin
play
role
atherogenesi
molecular
analysi
indic
nfjb
play
promin
role
format
atherosclerosi
abil
adher
element
promot
key
inflammatori
atherosclerosi
gene
sirna
target
nfjb
synthes
use
rapid
polymeras
chain
reaction
pcr
base
approach
gener
sens
antisens
sirna
separ
hairpin
loop
downstream
promot
transfect
vsmc
deriv
mice
mrna
protein
nfjb
nfjbdepend
transcript
respons
reduc
markedli
sirna
experi
shown
excess
apoptosi
vsmc
play
key
role
progress
atherosclerot
lesion
result
mani
cardiovascular
event
member
ccaat
enhancerbind
protein
cebp
famili
transcript
factor
link
apoptosi
vsmc
inhibit
sirna
reduc
creactiv
proteininduc
mrna
express
apoptosi
anoth
studi
demonstr
serin
proteas
could
releas
cytosol
mitochondria
promot
caspasedepend
apoptosi
apoptot
insult
remov
rna
interfer
shown
reduc
uv
lightinduc
apoptosi
cell
observ
may
suggest
new
option
treatment
atherosclerosi
cardiac
hypertrophi
compensatori
respons
varieti
physiolog
patholog
stimuli
prolong
hypertroph
respons
may
eventu
lead
arrhythmia
heart
failur
sudden
death
novel
human
gene
myofibrillogenesi
human
skelet
muscl
cdna
librari
interact
contractil
protein
exist
human
myocardi
myofibril
identifi
hypertrophi
model
hypertroph
cell
growth
induc
angiotensin
ii
incub
cultur
neonat
rat
cardiomyocyt
establish
transfect
neonat
cardiomyocyt
target
sequenc
found
mrna
protein
express
greatli
decreas
furthermor
compar
angiotensin
iitreat
group
rnai
ang
ii
group
show
decreas
surfac
area
cell
anoth
studi
report
transloc
hypertroph
transcript
factor
nfat
nucleu
cardiomyocyt
enhanc
nfat
transcript
activ
induc
angiotensin
ii
could
prevent
angiotensin
ii
also
stimul
activ
protein
kinas
c
contribut
cardiac
hypertrophi
inhibit
pathway
relat
stimul
atrial
natriuret
peptid
product
secret
observ
support
evid
sirna
gene
significantli
revers
restraint
protein
synthesi
inhibit
angiotensin
iiinduc
calcineurin
activ
accordingli
find
may
provid
better
understand
mechan
cardiac
remodel
new
insight
develop
novel
therapeut
strategi
cardiac
hypertrophi
viral
myocard
import
caus
heart
failur
dilat
cardiomyopathi
effect
approach
need
treat
viral
infect
gene
respons
affect
disord
identifi
gene
silenc
could
altern
therapeut
tool
especi
case
drug
therapi
resist
coxsac
kieviru
identifi
common
causal
agent
viral
myocard
exist
drug
therapi
limit
valu
mani
studi
shown
rnai
control
viral
infect
target
viral
gene
recent
schubert
et
al
found
two
independ
sirna
target
rnadepend
rna
polymeras
abl
reduc
viru
titer
respect
result
demonstr
enorm
potenti
rnai
approach
sirna
doubleexpress
vector
sidex
construct
achiev
simultan
express
sirna
one
plasmid
compar
convent
express
vector
sidex
show
substanti
gene
regul
mutat
target
rna
henc
believ
sidex
may
help
tool
achiev
sustain
silenc
virus
ultim
reduc
risk
emerg
viabl
mutant
yuan
et
al
report
sirna
target
viral
proteas
display
inhibit
replic
protect
sirnapretr
cell
hela
cell
murin
cardiomyocyt
moreov
found
administr
sirna
viral
infect
could
effect
inhibit
replic
indic
therapeut
potenti
find
impli
sirnabas
gene
drug
may
effect
therapi
viral
myocard
heart
failur
studi
show
heart
failur
common
lethal
condit
associ
variou
cvd
remain
lead
caus
morbid
mortal
one
import
featur
heart
failur
decreas
ca
uptak
sarcoplasm
reticulum
sr
sarcoplasmicendoplasm
reticulum
ca
atpas
neg
regul
phospholamban
plb
key
regul
cardiac
calcium
homeostasi
recent
find
demonstr
develop
sever
heart
failur
genet
muscl
lim
protein
mlp
anim
model
could
abolish
complet
target
ablat
plb
plb
consid
potenti
therapeut
target
improv
sr
ca
uptak
cardiac
function
twentyon
nucleotidesirna
duplex
symmetr
target
plb
mrna
synthes
introduc
neonat
rat
cardiac
myocyt
use
hemagglutin
viru
japan
hvj
envelop
vector
found
plb
sirna
result
signific
decreas
level
plb
mrna
protein
mrna
protein
calsequestrin
affect
affin
ca
also
increas
order
determin
effect
plb
rnai
cardiac
myocyt
ca
handl
impair
myocyt
expos
h
reactiv
oxygen
speci
result
decreas
plb
mrna
protein
level
achiev
watanab
strategi
use
plb
ablat
may
consid
novel
attract
candid
clinic
therapi
heart
failur
tabl
ii
summar
applic
target
gene
sirna
cvd
degen
disord
mark
progress
paralysi
bodi
muscl
end
prematur
death
age
patient
duchenn
muscular
dystrophi
dmd
major
muscular
dystrophi
children
mean
death
age
year
shorten
cardiomyopathi
complic
dmd
associ
mutat
dystrophin
gene
encod
key
compon
muscl
complex
compris
transmembran
cytoplasm
protein
number
protein
orthologu
c
elegan
rnai
knockdown
conserv
orthologu
result
phenotyp
similar
seen
dystrophin
rnai
appli
context
posit
transgen
background
provid
bidirect
control
gene
express
instanc
proteincod
gene
shrna
direct
gene
control
differ
induc
promot
transfect
cell
approach
appli
c
elegan
enabl
bidirect
control
transmembran
calcium
flux
attempt
unravel
poorli
understood
involv
elev
intracellular
calcium
dmd
c
elegan
calcium
channel
gainoffunct
mutat
use
enhanc
signal
rnai
knockdown
diminish
enhanc
calcium
signal
result
enhanc
muscl
degener
block
rnai
knockdown
thu
consider
potenti
applic
rnai
worm
fli
model
diseas
human
xlink
form
emerydreifuss
muscular
dystrophi
caus
loss
function
emerin
nuclear
membran
lemdomain
protein
emerin
member
lamin
class
protein
form
network
filament
inner
nuclear
envelop
essenti
maintain
nuclear
shape
dna
replic
transcript
although
c
elegan
equival
emerin
homolog
vertebr
counterpart
rnai
knockdown
produc
detect
phenotyp
c
elegan
stage
develop
suggest
function
loss
compens
anoth
pathway
test
hypothesi
overlap
function
structur
similar
function
known
establish
rnai
knockdown
alon
lethal
embryo
knockdown
absenc
lethal
embryo
thu
appli
rnai
approach
use
worm
model
suggest
overlap
function
rais
hope
gene
replac
strategi
therapi
emerydreifuss
muscular
dystrophi
spinal
muscular
atrophi
sma
associ
lower
motor
neuron
loss
spinal
cord
caus
mutat
surviv
motor
neuron
protein
smn
howev
clear
loss
smn
link
death
neuron
c
elegan
also
orthologu
smn
ubiquit
express
knockdown
worm
smn
protein
use
rnai
result
poor
embryon
viabil
sever
uncoordin
locomot
suggest
c
elegan
smn
protein
interact
similar
human
equival
drosophila
orthologu
smn
dsmn
use
model
diseas
drosophila
smn
gene
point
mutat
result
phenotyp
includ
abnorm
motor
behavior
function
impair
neuron
alter
synapt
transmiss
rnai
suppress
smn
drosophila
cell
result
signific
increas
apoptosi
pathway
involv
caspas
dronc
drice
effect
revers
caspas
inhibitor
zvadfmk
suggest
possibl
target
novel
therapi
alzheim
diseas
alzheim
diseas
ad
associ
accumul
insolubl
plaqu
amyloid
protein
ab
cn
well
intracellular
microfibrillar
tangl
along
loss
cholinerg
neuron
project
basal
forebrain
hippocampu
amygdala
plaqu
deposit
result
overproduct
ab
activ
csecretas
presenilin
thought
compon
c
elegan
model
use
microarray
studi
identifi
gene
upregul
downregul
result
heterolog
express
ab
also
prove
use
global
rnai
approach
design
identifi
gene
therapeut
opportun
sirna
regul
secret
ab
worm
ad
model
ab
express
muscl
clearli
need
improv
invertebr
model
ad
particularli
c
elegan
model
human
ab
express
neuron
secret
drosophila
model
ad
gener
express
amyloid
precursor
protein
app
known
app
process
ab
recent
model
ad
report
ab
express
cn
result
neurodegener
shorten
lifespan
model
offer
excit
possibl
rnaibas
studi
howev
rnai
appli
drosophila
cell
line
potenti
power
altern
approach
determin
pathway
involv
develop
alzheim
drosophila
equival
human
presenilin
psn
appear
involv
pathway
similar
vertebr
counterpart
earlyonset
famili
alzheim
exampl
associ
mutat
presenilin
gene
lead
oversecret
ab
rnai
knockdown
psn
result
blockag
csecretas
activ
provid
confirm
gene
role
csecretas
pathway
anoth
studi
use
rnai
reduc
express
two
gene
drosophila
cell
knockdown
gene
result
reduc
proteolyt
cleavag
ab
precursor
protein
notch
substrat
reduc
product
process
presenilin
suggest
requir
action
accumul
csecretas
increas
level
ab
ad
caus
csecretas
thought
counteract
asecretas
cleav
precursor
protein
middl
ident
asecretas
uncertain
recent
studi
show
rnai
knockdown
three
adam
disintegrin
metalloproteas
protein
human
glioblastoma
cell
elev
endogen
asecretas
indic
three
protein
involv
asecretas
activ
extens
approach
mammalian
system
also
enabl
potenti
gene
target
therapeut
intervent
identifi
exampl
sirna
target
bsecretas
bsite
app
cleav
enzym
shown
reduc
app
product
mous
cortic
neuron
offer
potenti
therapeut
approach
ad
least
nine
human
neurodegen
disord
caus
expans
cag
trinucleotid
repeat
rnai
recent
perform
two
preval
poli
q
diseas
huntington
diseas
hd
spinobulbar
muscular
atrophi
sbma
hd
autosom
domin
hereditari
brain
disord
progress
fatal
mutat
huntingtin
gene
result
involuntari
movement
chorea
cognit
impair
psychiatr
problem
depress
anxieti
hd
caus
expans
cag
trinucleotid
repeat
huntingtin
gene
expans
elong
ntermin
poli
q
stretch
protein
result
aggreg
format
neuron
intranuclear
inclus
number
treatment
strategi
propos
target
huntingtin
proteolysi
aggreg
transcript
sbma
xlink
motor
neuron
diseas
occur
adulthood
progress
diseas
result
loss
motor
neuron
lower
spinal
cord
brain
stem
caus
cag
trinucleotid
expans
first
exon
androgen
receptor
ar
unaffect
individu
poli
q
repeat
oppos
repeat
sbma
individu
poli
q
expans
result
intranuclear
aggreg
format
tissu
ar
gene
normal
express
one
laboratori
synthes
transgen
strain
express
poli
expans
fuse
yellow
fluoresc
protein
use
global
rnai
screen
screen
identifi
gene
result
prematur
appear
protein
aggreg
gene
identifi
mainli
involv
rna
metabol
protein
synthesi
protein
fold
protein
degrad
protein
traffick
would
interest
see
whether
gene
control
protein
aggreg
diseas
alzheim
drosophila
cell
engin
express
portion
human
ar
gene
cag
tract
repeat
tag
green
fluoresc
protein
cell
carri
cag
repeat
develop
green
fluoresc
protein
aggreg
aggresom
aggreg
form
much
faster
cag
repeat
use
rnai
direct
ar
protein
caplen
et
al
show
loss
ar
green
fluoresc
protein
aggreg
cotransfect
cell
therefor
rna
interfer
could
consider
therapeut
potenti
poli
q
neurodegen
disord
parkinson
diseas
disord
result
reduct
gene
express
rnai
use
mimic
gene
function
loss
parkinson
diseas
exampl
associ
loss
dopaminerg
neuron
sma
rnai
import
approach
explor
molecular
mechan
underli
parkinson
diseas
recent
approach
use
combin
overexpress
studi
explor
role
parkin
ubiquitin
ligas
dopamin
neuron
degener
drosophila
overexpress
parkin
shown
degrad
substrat
paelr
suppress
toxic
wherea
interf
endogen
parkin
promot
substrat
accumul
augment
neurotox
viralmedi
rnai
use
block
dopamin
synthesi
midbrain
neuron
adult
mice
studi
use
adenoassoci
viru
vector
promot
drove
express
shrna
direct
tyrosin
hydroxylas
enzym
requir
product
dopamin
inject
stereotact
substantia
nigra
one
side
brain
similar
vector
promot
express
random
shrna
inject
side
gfp
express
observ
halv
brain
dopamin
stain
reduc
side
brain
antityrosin
hydroxylas
shrna
inject
result
behavior
deficit
includ
loss
motor
perform
bilater
shrna
knockdown
dopamin
synthesi
result
reduc
motor
activ
respons
amphetamin
wellestablish
dopaminedepend
behavior
poorer
perform
rotarod
test
polyglutamin
disord
spinocerebellar
ataxia
type
also
known
machadojoseph
diseas
diseas
offer
compel
exampl
link
polymorph
exploit
miller
et
al
took
advantag
singlenucleotid
polymorph
g
fi
c
exist
tight
linkag
disequilibirum
cag
repeat
expans
silenc
express
mutant
diseas
protein
without
alter
level
normal
diseas
allel
c
polymorph
sit
immedi
repeat
normal
allel
g
miller
cowork
abl
gener
sirna
select
reduc
express
either
mutant
normal
allel
depend
specif
nucleotid
present
site
complementari
guid
strand
target
mrna
research
perform
studi
aim
determin
whether
rnai
could
use
target
pathogen
process
inherit
neurodegen
disord
caus
polyglutamin
expans
use
drosophila
human
tissu
cultur
model
spinobulbar
muscular
atrophi
diseas
caus
cag
expans
gene
encod
androgen
receptor
assess
abil
differ
sirna
select
inhibit
express
transcript
includ
truncat
human
androgen
receptor
gene
contain
differ
cag
repeat
length
repeat
found
rna
duplex
contain
cag
repeat
tract
induc
genespecif
inhibit
flank
androgen
receptor
sequenc
includ
sequencespecif
small
dsrna
nucleotid
rescu
toxic
activ
induc
plasmid
express
transcript
encod
expand
polyglutamin
tract
studi
purinerg
receptor
famili
difficult
smallmolecul
compound
avail
differenti
close
relat
receptor
antisens
rnai
approach
therefor
suitabl
strategi
address
medic
relev
painrel
gene
sirna
effici
inhibit
mrna
purinerg
receptor
gener
dorn
et
al
report
rnai
block
pathophysiolog
pain
respons
provid
relief
neuropath
pain
rat
diseas
model
rat
intrathec
infus
sirna
show
diminish
pain
respons
compar
missens
ms
sirnatr
untreat
control
model
agonistevok
pain
chronic
neuropath
pain
g
protein
import
mediat
opioid
receptorinduc
signal
g
subunit
involv
extracellular
signalregul
kinas
activ
induc
dopioid
receptor
decreas
g
express
rnai
significantli
block
signal
pathway
mous
neural
cell
kinas
activ
could
subsequ
restor
exogen
express
human
g
g
subunit
silenc
sirna
vanilloid
receptor
anoth
new
target
therapeut
approach
chronic
pain
nweller
et
al
reveal
sirna
target
mrna
potent
antisens
molecul
effici
phosphorothio
antisens
oligonucleotid
sixfold
activ
lock
nucleic
acid
gapmer
rnai
knockdown
remov
mrna
leav
parent
gene
intact
advantag
gene
knockout
studi
absenc
function
gene
may
induc
compensatori
express
may
explain
contradictori
find
research
doubl
cortic
syndrom
neurolog
disord
associ
doublecortin
dcx
gene
gene
delet
approach
fail
mimic
syndrom
mice
dcx
gene
delet
develop
normal
cortic
howev
direct
plasmidmedi
dsrna
dcx
caus
disrupt
radial
migrat
develop
cortic
neuron
suggest
neuron
lack
dcx
gene
select
altern
migrat
mechan
dcx
knockdown
model
might
therefor
serv
use
experiment
model
doubl
cortic
syndrom
neural
genet
basi
ethanol
addict
poorli
understood
complex
phenomenon
involv
sever
receptor
type
rnai
offer
complementari
approach
dissect
role
receptor
ethanol
addict
camino
butyr
acid
gaba
receptor
possibl
role
addict
rnai
reduct
express
subtyp
gaba
receptor
melanogast
reduc
behaviorimpair
effect
alcohol
nicotin
addict
despit
wellknown
health
hazard
common
around
world
rnai
promis
approach
unravel
gene
network
known
involv
invertebr
model
nicotin
toler
mani
studi
use
sirna
experiment
tool
dissect
cellular
pathway
lead
uncontrol
cell
prolifer
cancer
moreov
rnai
propos
potenti
treatment
cancer
former
system
deliv
antisens
oligonucleotid
treatment
cancer
target
antiapoptot
gene
shown
promis
clinic
trial
metastat
melanoma
use
combin
convent
chemotherapeut
rnai
target
oncogen
fusion
gene
bcrabl
mrna
cell
offer
promis
result
effect
downregul
mrna
bcrabl
oncoprotein
demonstr
multipl
investig
quantit
rtpcr
western
blot
analysi
respect
along
similar
line
acut
myeloid
transform
transloc
target
use
rnai
human
leukem
cell
line
studi
sirna
shown
potent
antisens
dna
suppress
gene
express
human
hepatoma
pancreat
cancer
cell
line
anoth
studi
four
differ
myeloid
leukemia
cell
line
transfect
dsrna
duplex
correspond
endogen
craf
gene
level
protein
markedli
decreas
transfect
cell
line
combin
rnai
craf
induc
apoptosi
cell
increas
sensit
dnadamag
agent
etoposid
activ
tnf
receptor
relat
death
receptor
induc
death
cancer
cell
may
simultan
activ
pathway
promot
cell
surviv
one
protein
inhibit
tnf
cell
death
pathway
call
flip
faddlik
enzym
flice
like
inhibitori
protein
flip
express
suppress
cancer
cell
use
sirna
cell
sensit
kill
death
receptor
activ
sever
studi
demonstr
efficaci
liposomeor
viral
vectormedi
transfect
cancer
cell
suppress
growth
andor
induc
death
next
step
develop
rnai
technolog
cancer
therapi
establish
method
target
tumor
cell
vivo
anoth
approach
might
target
gene
promot
angiogenesi
tumor
cell
requir
rich
suppli
blood
achiev
stimul
process
angiogenesi
may
therefor
possibl
inhibit
tumor
growth
target
vascular
endotheli
cell
involv
angiogenesi
evid
shown
deplet
crk
adaptor
protein
use
rnai
inhibit
migrat
cultur
vascular
endotheli
cell
anoth
studi
chang
cell
shape
reduct
clonogen
increas
suscept
transform
growth
factor
tgf
vitamin
differenti
note
express
inhibit
use
sirna
elucid
role
prevent
differenti
exampl
target
fusion
gene
result
oncoprotein
becom
novel
excit
approach
toward
kill
tumor
cell
applic
rnai
field
tumor
therapi
target
commonli
mutat
ra
oncogen
phase
iii
studi
antisens
dna
oligonucleotid
fail
ra
gene
frequent
mutat
human
cancer
make
difficult
oncogen
target
brummelkamp
et
al
report
success
inhibit
kra
kirstenrat
sarcoma
viral
oncogen
express
human
pancreat
carcinoma
cell
use
rnai
retrovir
system
led
loss
anchorageindepend
growth
tumorgen
furthermor
select
inhibit
mutant
kra
wildtyp
exemplifi
specif
rnai
potenti
gene
therapi
complementari
studi
ra
recent
rnairel
studi
tumorsuppressor
gene
promyelocyt
leukemia
pml
gene
reveal
regulatori
relationship
pml
major
histocompat
mhc
class
express
inhibit
pml
propos
downregul
mhc
class
seen
suggest
altern
method
employ
acut
promyelocyt
leukemia
cell
evad
host
immun
system
viral
oncogen
anoth
potenti
target
rnaimedi
tumor
therapi
select
inhibit
cell
infect
cancercaus
virus
shown
effect
studi
human
papilloma
viru
hpv
posit
human
cervic
carcinoma
cell
known
defect
repair
dna
doublestrand
break
make
cell
hypersensit
ioniz
radiat
protein
kinas
dnaactiv
catalyt
polypeptid
prkdc
gene
encod
catalyt
subunit
dnadepend
protein
kinas
dnapkc
integr
dna
repair
peng
et
al
use
rnai
target
prkdc
human
fibroblast
found
radiosensit
increas
rnai
also
use
studi
transcript
factor
implic
aberr
signal
pathway
respons
oncolog
diseas
exampl
success
rnaimedi
inhibit
nuclear
transcript
factor
cyclic
adenosin
monophosph
respons
element
bind
protein
implic
role
leukemogenesi
virtu
overexpress
bone
marrow
patient
activ
leukemia
human
immunodefici
viral
infect
dread
diseas
requir
attent
therapeut
drug
avail
treat
hiv
first
infecti
agent
target
rnai
perhap
life
cycl
pattern
gene
express
hiv
well
understood
hiv
messeng
rna
mrna
viral
genom
known
degrad
rna
interfer
novina
et
al
target
hiv
gag
gene
express
later
stage
hiv
replic
encod
gag
precursor
protein
proteolyt
cleav
polypeptid
form
core
hiv
function
uncoat
packag
viral
rna
cell
transfect
antigag
sirna
expos
hiv
vitro
product
decreas
import
find
antigag
sirna
also
inhibit
product
cell
stabli
integr
proviru
despit
success
rnaimedi
inhibit
hivencod
rna
cell
cultur
target
viru
directli
repres
substanti
challeng
clinic
applic
high
viral
mutat
rate
lead
mutant
escap
target
therefor
rnaimedi
downregul
cellular
cofactor
requir
hiv
infect
attract
altern
complementari
approach
transfect
cultur
cell
sirna
mrna
princip
hiv
receptor
express
surfac
cell
diminish
hiv
product
exposur
cell
viru
decreas
substanti
coreceptor
chemokin
receptor
anoth
logic
target
rna
interfer
homozyg
mutat
gene
receptor
deleteri
effect
immun
function
yet
confer
high
level
resist
hiv
infect
research
also
success
block
hiv
entri
target
human
peripher
blood
lymphocyt
use
lentivir
vector
transduc
shrna
human
lymphocyt
downregul
result
modest
nevertheless
signific
threeto
sevenfold
reduct
viral
infect
rel
control
inhibit
replic
success
sirna
tat
protein
hiv
protein
target
sirna
includ
nonstructur
protein
rev
gag
gene
may
potenti
manipul
stem
cell
virusresist
autolog
transplant
diseas
caus
virus
bacteria
continu
major
caus
death
worldwid
increas
caus
concern
emerg
resist
strain
potenti
use
infecti
pathogen
terrorist
respiratori
syncyti
viru
rotaviru
addit
target
rnaimedi
inhibit
initi
success
mammalian
cell
cultur
children
virus
respons
signific
proport
acut
respiratori
infect
gastroenter
respect
influenza
viru
anoth
recent
target
rnai
sirna
influenza
nucleocapsid
rna
transcriptas
lead
inhibit
replic
blockad
viral
rna
suggest
possibl
role
sirna
influenza
prophylaxi
therapi
effici
conveni
approach
plasmodium
falciparum
import
pathogen
third
world
countri
endem
malhotra
et
al
appli
rnai
technolog
two
cystien
proteas
gene
possibl
approach
treat
malaria
introduct
falciparum
dsrna
produc
morpholog
chang
food
vacuol
parasit
also
inhibit
requisit
hemoglobin
degrad
effect
help
investig
creat
model
pathogenesi
malaria
anoth
excit
applic
rnai
target
pathogen
fungu
cryptococcu
neoforman
propens
modifi
exogen
dna
high
frequenc
nonhomolog
recombin
gene
replac
challeng
c
neoforman
rnai
proven
valuabl
tool
probe
function
gene
product
potenti
involv
pathogen
fungu
use
capsular
gene
adenylosuccin
gene
initi
target
investig
shown
rnai
work
fungu
appli
technolog
studi
gene
function
take
advantag
rapidli
accumul
genom
sequenc
c
neoforman
hepat
induc
hepat
b
viru
hbv
hepat
c
viru
hcv
major
health
problem
vivo
applic
sirna
gene
hbv
also
led
effect
inhibit
viru
replic
subgenom
fulllength
hcv
replicon
replic
express
hcv
protein
stabli
transfect
human
hepatomaderiv
cell
use
studi
effect
variou
antivir
drug
sirna
target
intern
ribosom
entri
site
mrna
encod
viral
nonstructur
protein
inhibit
hcv
replicon
function
cell
cultur
furthermor
antihcv
sirna
deplet
cell
persist
replic
hcv
replicon
mccaffrey
et
al
perform
hydrodynam
tailvein
inject
sirna
antihcv
shrna
direct
effici
cleavag
hcv
sequenc
hcvluciferas
fusion
construct
mous
hepatocyt
vivo
use
method
silenc
either
fa
receptor
result
clearli
measur
protect
sever
fasinduc
liver
damag
antifa
sirna
hydrodynam
inject
antibodytr
mice
mice
surviv
day
observ
wherea
control
mice
die
within
day
endotheli
dihydrofol
reductas
dhfr
critic
regul
endotheli
tetrahydrobiopterin
h
b
nitric
oxid
bioavail
physiolog
patholog
condit
use
angiotensin
ii
model
system
found
rapid
transient
activ
endotheli
nad
p
h
oxidas
preced
h
depend
downregul
dhfr
eno
uncoupl
endothelium
signal
cascad
may
repres
univers
mechan
wherebi
eno
uncoupl
condit
associ
oxid
stress
atherosclerosi
hypertens
diabet
activ
vascular
nad
p
h
oxidas
document
specif
inhibit
endotheli
dhfr
rna
interfer
rnai
led
mark
reduct
endotheli
h
b
bioavail
evid
confirm
fasinduc
apoptosi
enlarg
infarct
size
reperfus
ischem
tissu
multipl
tissu
heart
kidney
brain
hamar
et
al
found
sirna
target
fa
could
inhibit
fa
express
murin
kidney
vivo
protect
mice
postischem
acut
renal
failur
small
interf
rna
emerg
novel
target
last
decad
still
infanc
howev
develop
area
last
decad
remark
revolution
basic
research
gene
function
ongo
research
worldwid
provid
valuabl
clue
regard
precis
mechan
sirna
therefor
sirna
multifacet
role
play
manag
variou
disord
current
mani
diseas
like
myocard
neurodegen
diseas
cancer
hiv
etc
incur
convent
drug
provid
symptomat
relief
abl
modul
cellular
aberr
advanc
understand
alter
cellular
mechan
well
gene
function
variou
patholog
state
target
cellular
compon
appear
promis
may
serv
breakthrough
altern
molecular
strategi
treatment
moreov
variou
approach
design
deliveri
sirna
includ
chemic
modif
viraland
nonviralmedi
deliveri
furthermor
appar
initi
cost
develop
treatment
option
may
seem
high
develop
may
reduc
overal
cost
diseas
therapi
well
cost
remiss
serv
reduc
cost
morbid
mortal
societi
whole
